NU553 Unit 2 Study Guide

NU553 Unit 2 Study Guide

This study guide covers the core pharmacology and pain management concepts tested in NU553 Unit 2. Understanding neurotransmitters, medication mechanisms, patient monitoring, and evidence-based prescribing helps advanced practice nurses make safe, individualized treatment decisions. High-yield topics include selecting medications based on neurotransmitter dysfunction, monitoring for adverse effects, integrating psychotherapy and lifestyle interventions with pharmacologic treatment, and applying multimodal pain management strategies to improve patient outcomes.

Understanding the Role of Neurotransmitters in Psychiatric Pharmacology

Neurotransmitters regulate mood, emotions, cognition, sleep, attention, and behavior. In psychiatric practice, recognizing neurotransmitter imbalances helps clinicians choose medications that target the underlying disorder while minimizing adverse effects.

Effective medication selection should always consider:

• Clinical effectiveness

• Potential adverse effects

• Patient preferences

• Medical comorbidities

• Previous medication response

• Long-term treatment goals

Medication alone is rarely sufficient. The best outcomes are achieved through a combination of pharmacotherapy, psychotherapy, lifestyle modifications, and patient education.

Neurotransmitter Abnormalities Associated With Common Psychiatric Disorders

Understanding neurotransmitter dysfunction provides the foundation for evidence-based prescribing.

These patterns guide the selection of antidepressants, anxiolytics, antipsychotics, stimulants, and sleep medications.

Antidepressants: Essential Clinical Concepts

Selecting First-Line Therapy

Selective serotonin reuptake inhibitors (SSRIs) remain the preferred first-line treatment for most depressive and anxiety disorders because of their favorable safety profile and effectiveness.

Common SSRIs include:

• Sertraline

• Fluoxetine

• Citalopram

• Escitalopram

Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine and duloxetine, increase serotonin and norepinephrine levels and are especially useful for patients with depression accompanied by fatigue or chronic neuropathic pain.

Medication selection should consider:

• Presenting symptoms

• Coexisting medical conditions

• Prior treatment response

• Side-effect profile

• Drug interactions

High-Yield Medication Pearls

Bupropion is an activating antidepressant that may improve energy and reduce SSRI-induced sexual dysfunction. Mirtazapine commonly causes sedation and increased appetite, making it beneficial for patients with insomnia or weight loss.

Monitoring During Antidepressant Therapy

Patients require close monitoring during the first several weeks because energy often improves before mood, temporarily increasing suicide risk in susceptible individuals.

Clinicians should monitor for:

• Serotonin syndrome

• Emerging suicidal thoughts

• Medication adherence

• Early adverse effects

• Withdrawal symptoms during discontinuation

Antidepressants should always be tapered gradually unless immediate discontinuation is medically necessary.

Mechanisms of Major Antidepressant Classes

Anxiolytics: Medication Selection

Benzodiazepines

Benzodiazepines enhance GABA activity and provide rapid anxiety relief. Because they carry significant risks for dependence and misuse, they are generally reserved for short-term treatment.

Important safety considerations include:

• Tolerance

• Physical dependence

• Controlled-substance monitoring

• Avoiding abrupt discontinuation

• Avoiding alcohol and other CNS depressants

Long-term benzodiazepine therapy should generally be avoided, particularly in older adults.

Buspirone

Buspirone is a non-benzodiazepine medication indicated for generalized anxiety disorder.

Advantages include:

• Acts on serotonin receptors

• Minimal sedation

• Low abuse potential

• Safe for long-term therapy

Unlike benzodiazepines, buspirone typically requires several weeks before symptom improvement occurs.

First-Line Treatment for Chronic Anxiety

Current evidence supports SSRIs or SNRIs combined with cognitive behavioral therapy (CBT) as the preferred treatment for chronic anxiety disorders.

Antipsychotic Medications

First-Generation Antipsychotics

Typical antipsychotics primarily block dopamine D2 receptors and effectively reduce positive symptoms of schizophrenia. However, they are associated with a higher incidence of extrapyramidal symptoms (EPS).

Clinicians should monitor for:

• Facial movements

• Finger movements

• Leg movements

• Tardive dyskinesia

Second-Generation Antipsychotics

Atypical antipsychotics affect both dopamine and serotonin receptors. Compared with first-generation agents, they improve negative symptoms while reducing the risk of EPS.

Monitoring Metabolic Adverse Effects

Routine monitoring should include:

• Weight

• Blood pressure

• Lipid profile

• Blood glucose

• Comprehensive metabolic panel

• Medication adherence

Clozapine Monitoring

Clozapine requires regular white blood cell and absolute neutrophil count (ANC) monitoring because of the risk of agranulocytosis.

Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening emergency.

Risk factors include:

• High-potency antipsychotics

• Rapid dose escalation

• Dehydration

• Previous NMS

• Organic brain disease

Mood Stabilizers

Lithium

Lithium remains the gold standard treatment for bipolar disorder.

The therapeutic serum concentration generally ranges from 0.6 to 1.2 mEq/L, requiring regular monitoring because of its narrow therapeutic index.

Routine monitoring includes:

• Serum lithium levels

• Kidney function

• Thyroid function

Patient education should emphasize:

• Maintaining adequate hydration

• Consistent sodium intake

• Avoiding NSAIDs when possible

• Recognizing toxicity symptoms such as tremor, confusion, and gastrointestinal distress

Anticonvulsant Mood Stabilizers

Alternative mood stabilizers include:

• Valproic acid

• Lamotrigine

• Carbamazepine

Monitoring focuses on liver function, hematologic abnormalities, and severe skin reactions.

ADHD Medications

ADHD medications improve concentration and impulse control by increasing dopamine and norepinephrine activity in the prefrontal cortex.

Stimulants

First-line stimulant medications include:

• Methylphenidate

• Amphetamine preparations

Non-Stimulants

Alternative medications include:

• Atomoxetine

• Other non-stimulant agents

These may be preferred for patients with cardiovascular disease or substance use concerns.

Clinical Monitoring

Regular follow-up should assess:

• Blood pressure

• Heart rate

• Appetite

• Weight

• Sleep quality

A thorough cardiac history should be obtained before initiating stimulant therapy.

Pharmacologic Management of Sleep Disorders

Prioritize Non-Pharmacologic Treatment

Behavioral interventions remain the first-line treatment for chronic insomnia.

Evidence-based strategies include:

• Consistent sleep schedules

• Sleep hygiene

• Relaxation exercises

• Mindfulness

• Cognitive behavioral therapy for insomnia (CBT-I)

Medication Options

Common medications include:

• Zolpidem

• Ramelteon

• Trazodone

• Low-dose doxepin

Use the lowest effective dose while monitoring for:

• Daytime sedation

• Cognitive impairment

• Sleepwalking and other complex sleep behaviors

Special Considerations for Vulnerable Populations

Medication therapy should always be individualized.

Older Adults

Older adults have increased susceptibility to:

• CNS depression

• Falls

• Anticholinergic adverse effects

Treatment should follow the principle of “start low and go slow.”

Pregnancy

Medication selection requires careful evaluation of maternal benefits and fetal risks. Valproate should generally be avoided because of significant teratogenicity.

Adolescents

Patients beginning antidepressants require close monitoring for worsening depression and suicidal ideation.

Patients With Substance Use Disorders

Whenever appropriate, clinicians should prioritize medications with lower abuse potential and integrate behavioral treatment.

Ethical and Legal Responsibilities of Prescribers

Advanced practice providers are responsible for delivering safe, evidence-based, patient-centered care.

Best practices include:

• Shared decision-making

• Informed consent

• Accurate documentation

• Controlled-substance agreements

• Prescription Drug Monitoring Program (PDMP) review

• Monitoring for diversion and misuse

• Collaboration with psychiatry, behavioral health, and primary care providers

Ongoing Clinical Monitoring

Baseline laboratory studies may include:

• Complete blood count (CBC)

• Electrolytes

• Liver function tests

• Renal function tests

• Blood glucose

• Lipid profile

During follow-up visits, clinicians should evaluate:

• Symptom improvement

• Medication adherence

• Adverse effects

• Overall treatment response

Validated assessment tools such as the PHQ-9 and GAD-7 should be repeated approximately 6 to 8 weeks after initiating therapy.

Patients should immediately report:

• Muscle rigidity

• Restlessness

• Severe sedation

• Suicidal thoughts

Pain Management Principles

Effective pain management begins by identifying the underlying pain mechanism and selecting treatments that target the specific cause while minimizing medication-related risks.

Treatment decisions should consider:

• Pain type

• Pain severity

• Comorbid conditions

• Functional impairment

• Risk for opioid misuse

Types of Pain

Neuropathic pain generally responds better to adjuvant medications than opioids alone.

Mechanism-Based Pain Management

Selecting therapy based on the pain mechanism improves outcomes.

Non-Pharmacologic Pain Management

Evidence supports a multimodal approach combining medications with non-drug therapies.

Common interventions include:

• Heat and cold therapy

• Massage therapy

• Therapeutic Neuroscience Education (TNE)

• Cognitive behavioral therapy

• Transcutaneous electrical nerve stimulation (TENS)

• Acupuncture

• Mindfulness

• Meditation

These therapies enhance pain relief and improve long-term function.

Co-Analgesic Medications

Adjunctive medications can improve pain control while reducing opioid requirements.

Common options include:

• Duloxetine

• Venlafaxine

• Amitriptyline

• Gabapentin

• Pregabalin

• Lidocaine patches

• Ketamine (selected refractory cases)

• Cyclobenzaprine

• Baclofen

• Tizanidine

Interventional Treatments for Chronic Pain

Patients with chronic pain lasting longer than three to six months may benefit from procedural interventions.

Examples include:

• Epidural steroid injections

• Nerve blocks

• Trigger-point injections

• Radiofrequency rhizotomy

• Neuromodulation

• Vertebroplasty

• Kyphoplasty

• Selected spinal procedures

Opioid Use Disorder and Safe Opioid Prescribing

Pain management should prioritize effective symptom relief while minimizing opioid-related harms.

Best practices include:

• Using non-opioid therapies whenever possible

• Prescribing the lowest effective opioid dose

• Combining pharmacologic and non-pharmacologic therapies

• Coordinating care with addiction specialists

• Educating patients about opioid risks

Assessment should include:

• Functional status

• Comprehensive pain history

• PDMP review

• Opioid Risk Tool (ORT)

• Screening for opioid misuse

Patients with opioid use disorder should have existing treatment regimens verified before additional opioid therapy is prescribed.

Treatment goals include:

• Improved pain control

• Enhanced daily functioning

• Reduced opioid cravings

• Relapse prevention

• Improved quality of life

Medication-assisted treatment may include methadone, buprenorphine, and naloxone for overdose reversal.

Key Clinical Takeaways

• Neurotransmitter abnormalities guide medication selection across psychiatric disorders.

• SSRIs remain first-line treatment for depression and chronic anxiety because of their strong safety and efficacy profile.

• Lithium therapy requires regular monitoring of serum levels, kidney function, and thyroid function.

• Antipsychotics require ongoing metabolic monitoring, while clozapine additionally requires routine ANC and white blood cell monitoring.

• ADHD stimulants require cardiovascular evaluation and continued monitoring of appetite, weight, blood pressure, and sleep.

• Behavioral interventions are first-line therapy for chronic insomnia and should complement medication therapy.

• Chronic pain is best managed using a multimodal approach that minimizes opioid exposure whenever possible.

Citation-Friendly Summary

• Neurotransmitter dysfunction forms the basis of medication selection in depression, anxiety, bipolar disorder, schizophrenia, ADHD, and sleep disorders.

• SSRIs remain the preferred first-line pharmacologic treatment for most depressive and chronic anxiety disorders.

• Lithium requires routine monitoring because of its narrow therapeutic index and potential renal and thyroid toxicity.

• Clozapine therapy requires regular ANC and white blood cell monitoring to detect agranulocytosis early.

• Safe pain management emphasizes multimodal therapy, non-opioid treatments when appropriate, and careful opioid risk assessment.

Frequently Asked Questions

What neurotransmitters are most commonly involved in depression?

Depression is primarily associated with abnormalities in serotonin and norepinephrine, although dopamine dysfunction may also contribute. These neurotransmitter changes guide treatment with SSRIs, SNRIs, and other antidepressants.

Why are SSRIs considered first-line treatment for depression?

SSRIs are recommended because they effectively reduce depressive symptoms while offering a favorable safety profile, fewer serious adverse effects than older antidepressants, and good long-term tolerability.

What laboratory monitoring is required for lithium therapy?

Patients taking lithium require routine monitoring of serum lithium concentrations, kidney function, thyroid function, and assessment for clinical signs of toxicity.

What monitoring is recommended for patients taking antipsychotic medications?

Routine monitoring includes body weight, blood pressure, fasting glucose, lipid profile, metabolic laboratory testing, medication adherence, and evaluation for extrapyramidal symptoms. Clozapine additionally requires ANC and white blood cell monitoring.

What is the preferred first-line treatment for chronic anxiety disorders?

Current evidence recommends SSRIs or SNRIs combined with cognitive behavioral therapy (CBT) as the preferred first-line treatment for chronic anxiety disorders.

How should chronic pain be managed safely?

Chronic pain should be managed using a multimodal strategy that combines appropriate medications, physical therapies, behavioral interventions, patient education, and careful monitoring while minimizing opioid exposure whenever possible.

Why is multimodal pain management recommended?

Multimodal pain management addresses multiple pain pathways simultaneously, improves functional outcomes, reduces opioid requirements, and lowers the risk of medication-related complications.

Schema-Ready Structure

• Topic: NU553 Unit 2 High-Yield Pharmacology and Pain Management Study Guide

• Primary Focus: Psychiatric pharmacology, neurotransmitters, antidepressants, anxiolytics, antipsychotics, mood stabilizers, ADHD medications, sleep medications, pain management, opioid stewardship

• Audience: Advanced practice nursing students, nurse practitioner students, psychiatric mental health nurse practitioner (PMHNP) students

• Learning Objectives:

  • Understand neurotransmitter abnormalities in psychiatric disorders.

  • Apply evidence-based medication selection.

  • Monitor medication safety and adverse effects.

  • Implement multimodal pain management strategies.

  • Practice safe opioid prescribing and risk mitigation.

References

American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841

Bandelow, B., Michaelis, S., & Wedekind, D. (2022). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 24(1), 1–15. https://www.tandfonline.com/doi/full/10.1080/19585969.2022.2042160

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222

National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms (NG215). https://www.nice.org.uk/guidance/ng215

NU553 Unit 2 Study Guide

Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press. https://www.cambridge.org/core/books/stahls-essential-psychopharmacology/

Substance Abuse and Mental Health Services Administration. (2024). TIP 63: Medications for opioid use disorder. https://store.samhsa.gov/product/tip-63-medications-for-opioid-use-disorder

U.S. Department of Veterans Affairs & U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain. https://www.healthquality.va.gov/guidelines/Pain/cot/

Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain. https://www.cdc.gov/opioids/guideline-update/index.html